– UK, Alderley Park – Redx Pharma (LON: REDX), the drug discovery and development company focused on cancer and fibrosis, today announced the appointment of Tom Burt to its Board as a Non-Executive Director effective from 4 August 2020.
Tom brings extensive investment experience in the sector to his role at Redx and will represent Sofinnova on the Board of Directors under the terms of the Subscription for shares by Sofinnova Crossover 1 SLP.
“We are delighted to welcome such an experienced director onto the Redx Board. I am looking forward to working with Tom and to ensuring that we grow Redx into a substantive biotech company.” said Board Chairman, Iain Ross.
About Tom Burt
Tom has been a Partner in the Crossover fund at Sofinnova Partners since its inception in 2017. Prior to this, he was a Research Analyst covering UK healthcare and life science equities at Peel Hunt, joining in 2015 after six years as an Investment Director at specialist life science investors; Ares Life Sciences and Novo Holdings. Before this, he spent four years in the Healthcare Investment Banking team at Piper Jaffray & Co. Tom holds an Engineering Doctorate from UCL in Biochemical Engineering & Bioprocess Leadership, an MSc in Biochemical Engineering and a BSc in Biotechnology.
Tom Burt commented: ” Redx is a company led by a highly talented management team with a proven track record for success, developing drugs in areas of high unmet medical need. I am pleased to be joining the board as a non-executive director and helping the Company drive forward its next phase of growth.”
About Redx Pharma Plc
Redx is a UK based biotechnology company whose shares are traded on AIM (LON: REDX). Redx’s vision is to become leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.
For more information: https://www.redxpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.